Skip to main content

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Status: complete

The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.

Inclusion Criteria

Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia or Richter's Transformation
Refractory to or relapsed after at least 1 prior treatment regimen
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria

Any major surgery, chemotherapy or immunotherapy within the last 14 days
Known hepatitis B virus, hepatitis C virus or HIV infection
Active autoimmune disorder (with the exception of autoimmune hemolytic anemia or ITP)

Have a question?
We're here to help

Chat with us: LiveHelp
Call us: 1-800-4-CANCER
(1-800-422-6237)

Which trials are right for you?

Use the checklist in our guide to gather the information you’ll need.